Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sunesis Pharmaceutic (SNSS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,172
  • Shares Outstanding, K 67,578
  • Annual Sales, $ 240 K
  • Annual Income, $ -26,620 K
  • 60-Month Beta 2.43
  • Price/Sales 270.85
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.75
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.18
  • Number of Estimates 3
  • High Estimate -0.12
  • Low Estimate -0.24
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.50 +91.58%
on 03/07/19
1.00 -4.00%
on 03/18/19
+0.43 (+81.13%)
since 02/21/19
3-Month
0.25 +284.00%
on 12/24/18
1.00 -4.00%
on 03/18/19
+0.72 (+300.00%)
since 12/21/18
52-Week
0.20 +380.00%
on 12/21/18
3.49 -72.49%
on 03/22/18
-2.39 (-71.34%)
since 03/21/18

Most Recent Stories

More News
Will Sunesis Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.

SNSS : 0.96 (+4.35%)
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2018. Loss from operations for the three months and year ended December...

SNSS : 0.96 (+4.35%)
Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up

Puma Biotech (PBYI) betters loss estimates in Q4 and also rides high on revenue beat. Nerlynx impresses with strong sequential and year-over-year growth.

CELG : 89.19 (+0.93%)
PBYI : 40.21 (+1.82%)
RHHBY : 33.9050 (-0.54%)
SNSS : 0.96 (+4.35%)
Sunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Thursday, March 7, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results...

SNSS : 0.96 (+4.35%)
Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock

Agios' (AGIO) loss tops estimates in Q4. Its precision medicine Tibsovo receives the FDA nod and leads to significant year-over-year revenue growth.

AGIO : 65.17 (+1.42%)
CELG : 89.19 (+0.93%)
BDSI : 5.21 (-1.14%)
SNSS : 0.96 (+4.35%)
Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates

Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.

MYL : 29.01 (+1.04%)
BDSI : 5.21 (-1.14%)
ACOR : 13.83 (+1.02%)
SNSS : 0.96 (+4.35%)
Safer Treatments Gain Market Traction as Cancer Occurence Continues to Grow

FinancialBuzz.com News Commentary

RNN : 0.55 (-1.79%)
OGEN : 0.65 (-26.14%)
ONCS : 0.53 (unch)
SNETD : 0.3900 (+14.71%)
SNET : 0.0106 (-4.50%)
SNSS : 0.96 (+4.35%)
Sunesis Announces Pricing of $20 Million Offering of Securities

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and (ii) 17,000 shares of its non-voting Series E...

SNSS : 0.96 (+4.35%)
Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies

- 50 mg Cohort Completed -

SNSS : 0.96 (+4.35%)
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting

Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from the Company's Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory...

SNSS : 0.96 (+4.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade SNSS with:

Business Summary

Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing...

See More

Key Turning Points

2nd Resistance Point 1.04
1st Resistance Point 0.98
Last Price 0.96
1st Support Level 0.87
2nd Support Level 0.81

See More

52-Week High 3.49
Fibonacci 61.8% 2.23
Fibonacci 50% 1.85
Fibonacci 38.2% 1.46
Last Price 0.96
52-Week Low 0.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar